DRUG
Teduglutide
bridging intestinal failure with teduglutide until reconstruction
Status
Completed
Phase
Not applicable
Enrollment
1
Locations
1
Results
Not posted
Publications
0
Study summary
In this case report the investigators present a novel strategy for using teduglutide as a bridging therapy to intestinal reconstruction.
Interventions
DRUG
bridging intestinal failure with teduglutide until reconstruction
Timeline
First posted
Jun 7, 2021
Study start
Jan 1, 2019
Primary completion
Dec 31, 2019
Study completion
Dec 31, 2019
Results posted
Not reported
Registry updated
Jun 7, 2021
Outcomes
enteral autonomy (complete discontinuation of parenteral support)
Time frame · 6 months
observe if enteral autonomy may be achieved before reconstruction
Not reported in the indexed record.
Eligibility
Inclusion Criteria: short bowel syndrome Exclusion Criteria: * \<18 years
Study locations
Austria. Showing up to 24 locations stored in the fast local snapshot.
Medical University of Vienna
Vienna, Austria
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Takeda · Short Bowel Syndrome
Phase 3
Recruiting
13
2026-06
International Centre for Diarrhoeal Disease Research, Bangladesh · Environmental Enteric Dysfunction
Phase 2
Not yet recruiting
55
2026-04
Takeda · Short Bowel Syndrome
Not applicable
Active, not recruiting
250
2026-04
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
12
2026-03
Meyer Children's Hospital IRCCS · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
50
2026-02
Takeda · Short Bowel Syndrome (SBS)
Not applicable
Recruiting
600
2026-01
Shire · Short Bowel Syndrome
Not applicable
Active, not recruiting
1,806
2025-10
Assistance Publique - Hôpitaux de Paris · Short Bowel Syndrome
Phase 4
Completed
25
2025-09
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.